Engineered immune cells take on deadly brain tumors in first human trial
NCT ID NCT06186401
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial tests a new treatment for glioblastoma, an aggressive brain cancer. Researchers take a patient's own immune cells, modify them in the lab to better recognize and attack the tumor, and then infuse them back. The study involves 20 adults whose tumors have a specific marker (EGFRvIII) and aims to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- Can a Two-Drug combo outsmart resistant lung cancer?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy